Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of rilematovir in high-risk adult outpatients with RSV infection
2020-005980-30Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing rilematovir with placebo (2 arms). Primary endpoint: Time to resolution of RSV lower respiratory tract disease symptoms. Started Jun 2021; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2020-005980-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005980-30.